Interactions Between Endothelial Secretogogues

References

• Gryglewski R J. Interactions between nitric oxide and prostacyclin. Semin Thromb Hemost 1993; 19: 158–66
   PubMed Web of Science ®Google Scholar
• Gryglewski R J, Moncada S, Palmer R MJ. Bioassay of prostacyclin and endothelium-derived relaxing factor (EDRF) from porcine aortic endothelial cells. Br J Pharmacol 1986; 87: 685–94
   PubMed Web of Science ®Google Scholar
• Lidbury P S, Thiemermann Ch, Korbut R, Vane J R. Endothelins release tissue plasminogen activator and prostanoids. Eur J Pharmacol 1990; 186: 205–12
   Google Scholar
• Kaplan K L, Mather T, De Marco L, Solomon S. Effect of fibrin on endothelial cell production of prostacyclin and tissue plasminogen activator. Atherosclerosis 1989; 9: 43–9
   Google Scholar
• Gryglewski R J. Paradoxical thrombogenic effects of thrombolytic drugs: experimental and clinical data. Anaesthesia Pain Intensive Care and Emergency Medicine, A Gullo. Fogliazza editore Milano, Milan 1994; 713–20
   Google Scholar
• Stamler J S, Vaughan D E, Loscalzo J. Synergistic disaggregation of platelets by tissue-type plasminogen activator, prostaglandin E1, and nitroglycerin. Circ Res 1989; 65: 796–804
   PubMed Web of Science ®Google Scholar
• Stadler J S, Stefanovic-Racic M, Billiar T R, et al. Articular chondrocytes synthesize nitric oxide in response to cytokines and lipopolysaccharides. J Immunol 1991; 147: 3915–20
   PubMed Web of Science ®Google Scholar
• Awlerkosz T A, Mitchell J A, Tomilnson T A. Relationship between different isoforms of nitric oxide synthase and cyclooxygenase in various cell types. Pol J Pharmacol 1994; 46: 587–92
   Google Scholar
• Kanner J, Harel S, Granlt R. Nitric oxide, an inhibitor of lipid oxidation by lipoxygenase, cyclooxygenase and hemoglobin. Lipids 1992; 27: 46–9
   PubMed Web of Science ®Google Scholar
• Salvemlni D, Misko T P, Masferrer L, Selbert K, Currie M G, Needleman P. Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA 1993; 90: 7240–4
   Google Scholar
• Inoue T, Shigeto M, Koh E, Ogihara T. Nitric oxide mediates interleukin-1 prostaglandin E2 production by vascular smooth muscle cells. Biochem Biophys Res Commun 1993; 194: 105–9
   Google Scholar
• Corbett J A, Kwon G, Turk J, McDaniel M L. IL-1 beta induces the coexpression of both nitric oxide synthase and cyclooxygenase by islets of Langerhans: activation of cyclooxygenase by nitric oxide. Biochemistry 1993; 32: 13767–70
   PubMed Web of Science ®Google Scholar
• Franchi A M, Chaud M, Rettori V, Suburo A, McCann M S, Gimeno M. Role of nitric oxide in eicosanoid synthesis and uterine motility in estrogen-treated rat uteri. Proc Natl Acad Sci USA 1994; 91: 539–43
   PubMed Web of Science ®Google Scholar
• Marotta P, Sautebin L, Di Rosa M. Modulation of the induction of nitric oxide synthase by eicosanoid in the murine macrophage cell line J774 cells. Br J Pharmacol 1992; 107: 640–1
   Google Scholar
• Gillard T, Mülsch A, Klein H, Decker K. Regulation by prostaglandin E2 of cytokine-elicited nitric oxide synthesis in rat liver macrophages. Biol Chem Hoppe Seyler 1992; 373: 897–902
   Google Scholar
• Griscavage J M, Rogers N E, Sherman M P, Ignarro L J. Inducible nitric oxide synthase from a rat alveolar macrophage cell line is inhibited by nitric oxide. J Immunol 1993; 151: 6329–37
   PubMed Web of Science ®Google Scholar
• Kuhn M, Otten A, Jürgen C, Frölich C, Förstermann U. Endothelial cyclic GMP and cyclic AMP do not regulate the release of endothelium-derived relaxing factor/nitric oxide from bovine aortic endothelial cells. J Pharmacol Exp Ther 1991; 256: 677–82
   Google Scholar
• Radomskl M W, Palmer R MJ, Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol 1987; 92: 181–7
   Google Scholar
• Radomski M W, Palmer R MJ, Mondaca S. The anti-aggregatory properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987; 92: 639–46
   PubMed Web of Science ®Google Scholar
• Lidbury P S, Antunes E, De Nucci G, Vane J R. Interactions of iloprost and sodium nitroprusside on vascular smooth muscle and platelet aggregation. Br J Pharmacol 1989; 98: 1275–80
   PubMed Web of Science ®Google Scholar
• Sinzinger H, Fitscha P, O'Grady J, Rauscha F, Rogati W, Vane J R. Synergistic effect of prostaglandin E1 and isosorbide dinitrate in peripheral vascular disease. Lancet 1990; 335: 627–8
   Google Scholar
• Bleroń K, Grodzlńska L, Kostka-Trabka E, Gryglewski R J. Prostacyclin and molsidomine synergise in their fibrinolytic and anti-platelet actions in patients with peripheral arterial disease. Wien Klin Wochenschr 1993; 105: 7–11
   Google Scholar
• Bowen R, Haslam R J. Effects of nitrovasodilators on platelet cyclic nucleotide levels in rabbit blood; role of cyclic AMP in synergistic inhibition of platelet function by SIN-1 and prostaglandin E1. J Cardiovasc Pharmacol 1991; 17: 424–33
   Google Scholar
• Noite C, Eigenthalter M, Schanzenbacher P, Walters V. Endothelial cell-dependent phosphorylation of a platelet protein mediated by c-AMP and c-GMP elevating factors. J Biol Chem 1991; 266: 14808–12
   Google Scholar
• Taddel S, Viridis A, Mattel R, Salvetti A. Vasodilatation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993; 21: 929–33
   PubMedGoogle Scholar
• Cockroft J R, Chowleńczyk P J, Benjamin N, Ritter J M. Preserved endothelium-dependent vasodilatation in patients with essential hypertension. N Engl J Med 1994; 330: 1036–40
   Google Scholar
• Gryglewski R J. Nitric oxide and atherosclerosis. Thromb Haemorrh Disord 1990; 2: 1–9
   Google Scholar
• Chiopicki S, Gryglewski R J. Nitric oxide is a major mediator in reactive hyperaemia evoked by a brief coronary occlusion in the guinea pig heart. Eur J Pharmacol 1993; 241: 117–20
   Google Scholar
• Lugnier C, Komas N. Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: role in vasodilatation. Eur Heart J 1993; 14(suppl 1)141–8
   Google Scholar
• Soothgate K, Newby A C. Serum-induced proliferation of rabbit aortic smooth muscle cells from the contractile state is inhibited by 8-Br-cAMP but not 8-Br-cGMP. Atherosclerosis 1990; 82: 113–23
   Google Scholar
• Lüscher T F. The endothelium and cardiovascular disease—a complex relation. N Engl J Med 1994; 330: 1081–3
   PubMed Web of Science ®Google Scholar
• Gryglewski R J, Bunting S, Moncada S, Flower R J, Vane J R. Arterial walls are protected against deposition of platelet thrombi by a substance (Prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins 1976; 12: 685–713
   PubMed Web of Science ®Google Scholar
• Gryglewski R J, Dembińska-Kleć A, Zmuda A, Gryglewska T. Prostacyclin and thromboxane A2 biosynthesis capacities of heart, arteries and platelets at various stages of experimental atherosclerosis in rabbits. Atherosclerosis 1978; 31: 385–94
   PubMed Web of Science ®Google Scholar
• Szczeklik A, Gryglewski R J. Low-density lipoproteins (LDL) are carriers for lipid peroxides and invalidate prostacyclin (PGI2) bio-synthesis in arteries. Artery 1980; 7: 488–95
   PubMedGoogle Scholar
• Witztum J L. The oxidation hypothesis of atherosclerosis. Lancet 1984; 344: 793–5
   Google Scholar
• Tokunaga O, Yamada T, Fan J L, Watanabe T. Age-related decline in prostacyclin synthesis by human aortic endothelial cells. Qualitative and quantitative analysis. Am J Pathol 1991; 39: 941–9
   Google Scholar
• Aoyama T, Yui Y, Morishita H, Kawal C. Prostaglandin I2 half-life regulated by high density lipoprotein is decreased in myocardial infarction and unstable angina pectoris. Circulation 1990; 81: 1784–91
   Google Scholar
• Peto J, Mihai K, Makary A. Low level of prostacyclin as a risk of ischaemic heart disease. Int J Cardiol 1991; 30: 237–9
   PubMed Web of Science ®Google Scholar
• Loosemore T M, Chalmers T C, Dormandy J A. A metaanalysis of randomized placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease. Int Angiol 1994; 13: 133–42
   Google Scholar
• Pomerantz K B, Hajjar D P. High-density lipoprotein-induced cholesterol efflux from arterial smooth muscle cell derived foam cells: functional relationship of the cholesteryl ester cycle and eicosanoid biosynthesis. Biochemistry 1990; 29: 1892–9
   Google Scholar
• Willis A L, Smith D L. Therapeutic impact of eicosanoids in atherosclerotic disease. Eicosanoids 1989; 2: 69–99
   Google Scholar
• Sinzinger H, Virgolini I, Lupatelli G, Molinari E, Gerakakis A, Angelberger P. Prostaglandin E1 decreases the low-density-lipoprotein entry into rabbit arterial wall. Br J Pharmacol 1991; 103: 1626–8
   Google Scholar
• Fitzgerald G A, Smith B, Pedersen A K, Brash A R. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl Med 1984; 310: 1060–5
   Google Scholar
• Wang T, Falardeau P, Powell W S. Synthesis of prostaglandins and thromboxane B2 in cholesterol-fed rabbits. Arterioscler Thromb 1991; 11: 501–8
   Google Scholar
• Vane J R, Botting R M. Regulatory mechanisms of the vascular endothelium: an update. Pol J Pharmacol 1994; 46: 497–521
   Google Scholar
• Vane J R, Mitchell J A, Appleton I, et al. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci USA 1994; 91: 2046–50
   PubMed Web of Science ®Google Scholar
• Flavahan N A. Atherosclerosis or lipoprotein-induced endothelial dysfunction. Circulation 1992; 85: 1927–38
   PubMed Web of Science ®Google Scholar
• Rubanyl G M. Reversal of hypercholesterolemia-induced endothelial dysfunction by L-arginine. Circulation 1991; 83: 118–20
   Google Scholar
• Chester A H, O'Neal G, Moncada S, Tadjkarimi S, Yacoub M H. Low basal and stimulated level of nitric oxide in atherosclerotic epicardial coronary arteries. Lancet 1990; 336: 897–900
   PubMed Web of Science ®Google Scholar
• Woditsch I, Schrör K. Reduced endothelium-dependent relaxation at enhanced NO release in hearts of hyper-cholesterolaemic rabbits. Br J Pharmacol 1994; 111: 1035–40
   PubMed Web of Science ®Google Scholar
• Gilligan D M, Guetta V, Panza J A, Garcia C E, Quyyumi A A, Cannon R O. Selective loss of microvascular endothelial function in human hypercholesterolemia. Circulation 1994; 90: 35–41
   PubMed Web of Science ®Google Scholar
• Casino P R, Kilcoyne C M, Quyyumi A A, Hoeg J M, Panza J A. The role of nitric oxide in endothelium-dependent vasodilation of hypercholesterolemic patients. Circulation 1993; 88: 2541–7
   PubMed Web of Science ®Google Scholar
• Rossitch E, Alexander E, III, Black P M, Cooke J P. L-arginine normalizes endothelial function in cerebral vessels from hypercholesterolemic rabbits. J Clin Invest 1991; 87: 1295–9
   PubMed Web of Science ®Google Scholar
• Cooke J P, Singer A H, Tsao P, Zera P, Rowan R A, Billingham M E. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest 1992; 90: 1168–72
   PubMed Web of Science ®Google Scholar
• Drexier H, Zelcher A M, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 1991; 338: 1546–50
   Google Scholar
• Creager M A, Gallagher S J, Girerd J, Coleman S M, Dzau V J, Cooke J P. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1992; 90: 1248–53
   PubMed Web of Science ®Google Scholar
• Taguchl J, Abe J, Okazakl H, Takuwa Y, Kurokawa K. L-arginine inhibits neointimal formation following balloon injury. Life Sci 1993; 53: PL387–92
   Google Scholar
• Cayatte A J, Palacino J J, Horten K, Cohen R A. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb 1994; 14: 753–9
   PubMedGoogle Scholar
• Ohgushi M, Kuglyama K, Fukunaga K, et al. Protein kinase C inhibitors prevent impairment of endothelium-dependent relaxation by oxidatively modified LDL. Arterioscler Thromb 1993; 13: 1525–32
   PubMedGoogle Scholar
• Yang X, Cai B, Sclacca R R, Cannon J P. Inhibition of inducible nitric oxide synthase in macrophages by oxidized low-density lipoproteins. Circ Res 1994; 74: 318–28
   PubMed Web of Science ®Google Scholar
• Galle J, Mülsch A, Busse R, Bassenge E. Effects of native and oxidized low density lipoproteins on formation and inactivation of endothelium-derived relaxing factor. Arterioscler Thromb 1991; 11: 198–203
   PubMed Web of Science ®Google Scholar
• Hogg N, Kalyanaraman B, Joseph J, Struck A, Parthasarathy S. Inhibition of low-density lipoprotein oxidation by nitric oxide. FEBS Lett 1993; 334: 170–4
   PubMed Web of Science ®Google Scholar
• Gryglewski R J, Korbut R, Ocetklewicz A, Stachura J. In vivo method for quantitation of anti-platelet potency of drugs. Naunyn Schmiedebergs Arch Pharmacol 1978; 302: 25–30
   PubMedGoogle Scholar
• Eisenberg P R, Sherman L A, Jarre A S. Paradoxic elevation of fibrinopeptide a after streptokinase: evidence for continued thrombosis despite fibrinolysis. J Am Coll Cardiol 1987; 10: 527–9
   PubMedGoogle Scholar
• Szczeklik A, Droplńskl J, Radwan J, Krzanowski M. Persistent generation of thrombin after acute myocardial infarction. Arterioscler Thromb 1992; 12: 548–53
   Google Scholar
• Gorog P, Ridler C D, Kovacs I B. Heparin inhibits spontaneous thrombolysis and the thrombolytic effect of both streptokinase and tissue-type plasminogen activator. J Intern Med 1990; 227: 125–32
   Google Scholar
• Udvardy M, Harsfalvi J, Boda Z, Rak K. Thrombotic changes in haemostasis following intravenous streptokinase treatment for acute myocardial infarction. Thromb Haemost 1990; 63: 146–7
   PubMed Web of Science ®Google Scholar
• Munkvad S, Brandslund I, Gram J, Jespersen J. The complement system is activated by streptokinase, but not by combined heparin-recombinant tissue-type plasminogen activator therapy in patients with myocardial infarction: a placebo-controlled study. Coron Artery Dis 1991; 2: 889–95
   Google Scholar
• Owen J, Friedman K D, Grossman B A, Wilkins C, Berke A D, Powers E R. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood 1988; 72: 616–20
   PubMed Web of Science ®Google Scholar
• Seitz R, Blanke H, Prätorius G, Strauer B E, Egbring R. Increased thrombin activity during thrombolysis. Thromb Haemost 1988; 59: 541–2
   PubMed Web of Science ®Google Scholar
• Gulba D C, Barthels M, Westhoff-Bleck M, et al. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction: relevance for the success of therapy. Circulation 1991; 83: 937–44
   PubMed Web of Science ®Google Scholar
• Fitzgerald D J, Catella F, Roy L, FltzGerald G A. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988; 77: 142–50
   PubMed Web of Science ®Google Scholar
• Ohlstein E H, Storer B, Fujita T, Shebuski R J. Tissue-type plasminogen activator and streptokinase induce platelet hyperaggregability in the rabbit. Thromb Res 1987; 46: 575–85
   PubMedGoogle Scholar
• Rudd M A, George D, Amarante P, Vaughan D E, Loscalzo J. Temporal effects of thrombolytic agents on platelet function in vivo and their modulation by prostaglandins. Circ Res 1990; 67: 1175–81
   PubMed Web of Science ®Google Scholar
• Penny W F, Ware J A. Platelet activation and subsequent inhibition by plasmin and recombinant tissue-type plasminogen activator. Stood 1992; 79: 91–8
   Google Scholar
• Purl R N, Zhou F X, Colman R F, Colman R W. Plasmin-induced platelet aggregation is accompanied by cleavage of aggregin and indirectly mediated by calpain. Am J Physiol 1990; 259: C862–8
   Google Scholar
• Winters K J, Santoro S A, Miletich J P, Eisenberg P R. Relative importance of thrombin compared with plasmin-mediated platelet activation in response to plasminogen activation with streptokinase. Circulation 1991; 84: 1552–60
   PubMed Web of Science ®Google Scholar
• Montrucchio G, Bergerons S, Bussollno F, et al. Streptokinase induces intravascular release of platelet-activating factor in patients with acute myocardial infarction and stimulates its synthesis by cultured human endothelial cells. Circulation 1993; 88: 1476–83
   Google Scholar
• Ohman E M, Topol E J, Califf R M, et al. An analysis of the cause of early mortality after administration of thrombolytic therapy. Coron Artery Dis 1993; 4: 957–64
   Google Scholar
• Purl R N, Hu C J, Matsueda R, Umeyama H, Colman R W. Aggregation of washed platelets by plasminogen and plasminogen activators is mediated by plasmin and is inhibited by a synthetic peptide disulfide. Thromb Res 1992; 65: 533–47
   Google Scholar